Spinraza

E24879

antisense oligonucleotide biologic medicinal product medication orphan drug prescription drug

Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (3)

Label	Occurrences
nusinersen	5
Spinraza canonical	4
SMN2	1

How this entity was disambiguated

This entity first appeared as the object of triple T195375 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: Spinraza
Context triple: [Biogen, hasProduct, Spinraza]

A. Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
B. Philortyx
Philortyx is a genus of New World quails known for their ground-dwelling habits and occurrence in scrub and grassland habitats of the Americas.
C. Abital
Abital is one of the lesser-known wives of the biblical King David, mentioned in the Hebrew Bible as the mother of his son Shephatiah.
D. BB-37
BB-37 is the hull number of USS Oklahoma, a Nevada-class battleship of the United States Navy that was sunk during the attack on Pearl Harbor in 1941.
E. Neuralink
Neuralink is a neurotechnology company developing implantable brain–computer interfaces aimed at enabling direct communication between the human brain and computers.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: Spinraza
Target entity description: Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.

A. Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
B. Philortyx
Philortyx is a genus of New World quails known for their ground-dwelling habits and occurrence in scrub and grassland habitats of the Americas.
C. Abital
Abital is one of the lesser-known wives of the biblical King David, mentioned in the Hebrew Bible as the mother of his son Shephatiah.
D. BB-37
BB-37 is the hull number of USS Oklahoma, a Nevada-class battleship of the United States Navy that was sunk during the attack on Pearl Harbor in 1941.
E. Neuralink
Neuralink is a neurotechnology company developing implantable brain–computer interfaces aimed at enabling direct communication between the human brain and computers.
F. None of above. chosen

Statements (49)

Predicate	Object
instanceOf	antisense oligonucleotide ⓘ biologic medicinal product ⓘ medication ⓘ orphan drug ⓘ prescription drug ⓘ
approvedBy	European Medicines Agency ⓘ Food and Drug Administration ⓘ surface form: U.S. Food and Drug Administration
developedBy	Biogen ⓘ Ionis Pharmaceuticals ⓘ
hasActiveIngredient	Spinraza self-linksurface differs ⓘ surface form: nusinersen
hasAdministrationSite	cerebrospinal fluid ⓘ
hasATCCode	M09AX07 ⓘ
hasBrandOwner	Biogen ⓘ
hasCommonAdverseEffect	back pain ⓘ constipation ⓘ headache ⓘ nausea ⓘ respiratory infection ⓘ
hasDosageForm	solution for injection ⓘ
hasGenericName	Spinraza self-linksurface differs ⓘ surface form: nusinersen
hasInternationalNonproprietaryName	Spinraza self-linksurface differs ⓘ surface form: nusinersen
hasLoadingDoseRegimen	four loading doses over approximately two months ⓘ
hasMaintenanceDoseRegimen	one dose every four months ⓘ
hasPregnancyCategory	not assigned; use only if potential benefit justifies potential risk ⓘ
hasSeriousAdverseEffect	coagulation abnormalities ⓘ renal toxicity ⓘ thrombocytopenia ⓘ
hasTherapeuticArea	neurology ⓘ rare diseases ⓘ
increasesProductionOf	survival motor neuron protein ⓘ surface form: SMN protein survival motor neuron protein ⓘ
indicatedFor	adult patients with spinal muscular atrophy ⓘ pediatric patients with spinal muscular atrophy ⓘ
isAdministeredBy	healthcare professional ⓘ
isFirstDrugApprovedFor	spinal muscular atrophy ⓘ
isUsedAs	disease-modifying therapy for spinal muscular atrophy ⓘ
legalStatusInEuropeanUnion	prescription only ⓘ
legalStatusInUnitedStates	prescription only ⓘ
mechanismOfAction	antisense oligonucleotide that modulates SMN2 pre-mRNA splicing ⓘ
modifiesGeneExpression	SMN2 ⓘ
regulatoryApprovalYear	2016 ⓘ
requiresMonitoringOf	coagulation parameters ⓘ platelet count ⓘ renal function ⓘ
routeOfAdministration	intrathecal ⓘ lumbar puncture ⓘ
targetsGene	Spinraza self-linksurface differs ⓘ surface form: SMN2
treats	5q spinal muscular atrophy ⓘ spinal muscular atrophy ⓘ

How these facts were elicited

Referenced by (10)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen → hasProduct → Spinraza ⓘ

Biogen → hasNotableDrug → Spinraza ⓘ

Spinraza → hasGenericName → Spinraza self-linksurface differs ⓘ